港股異動丨乳製品股走強 發盈喜原生態牧業一度飆漲至48.8%
港股乳製品股走強,其中,原生態牧業一度飆漲至48.8%,中國飛鶴漲1.5%,蒙牛乳業、優然牧業、澳優、中國聖牧均上漲。光大證券指出,乳企對於本次春節及25年全年的增長目標設定更爲理性,費用投放更爲謹慎,對利潤端提出更高要求。高盛此前表示,2024年中國新生兒數量達954萬,同比增長6%,高於高盛預期和聯合國預測。在基本情景下,預計到2035年新生兒數量相對穩定。個股方面,原生態牧業盈喜,預計2024年純利達到2.7億至3.2億元,而截至2023年12月31日止年度的淨虧損約爲人民幣3.397億元。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.